Anti-cancer effects of Alternol and Alteronol on human cancers

doi:10.3760/cma.j.issn.1673-422X.2017.06.013

Abstract

Abstract: Alternol and Alteronol are two small chemical compounds purified from a mutant fungal. The in vitro and in vivo experimental studies have confirmed their potent anticancer effect. In vitro studies show that they can inhibit cell division and proliferation of a variety of tumors including prostate cancer, osteosarcoma and melanoma. They exert their anticancer effects by attenuating cell cycle protein expression and causing cell cycle arrest, suppressing tumor cell invasion and metastasis, reducing new blood vessel formation, decreasing the expression of antiapoptotic proteins Bcl2 in malignant cells, and stimulating oxygen free radical accumulation. However, there is no significant cytotoxic effect on benign cells. Animal experiments show that these two compounds significantly inhibit xenograft growth derived from a variety of human malignant tumors, while there is no obvious side effect on normal tissue or organs. In conclusion, these two compounds are worthy to be developed as novel anticancer drugs.

Key words: Neoplasms, Apoptosis, Cell cycle, Alternol, Alteronol

Liu Lihua, Li Benyi. Anti-cancer effects of Alternol and Alteronol on human cancers[J]. Journal of International Oncology, 2017, 44(6): 452-.

References

［1］ Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. Ⅵ. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia［J］. J Am Chem Soc, 1971, 93(9): 2325-2327. ［2］ Chen JP, Duan LL, Wang R, et al. Microorganism for producing the novel compound: US, 20090203775A1［P］. 20090813. ［3］ Duan LL, Chen H, Chen JP, et al. The fermentation process of the new anticancer compound Alternol［J］. J Shenyang Pharma Univ, 2009, 26(4): 316-323. ［4］ Liu ZZ, Zhu J, Sun B, et al. Alternol inhibits proliferation and induces apoptosis in mouse lymphocyte leukemia (L1210) cells［J］. Mol Cell Biochem, 2007, 306(1/2): 115-122. DOI: 10.1007/s1101000795600. ［5］ Liu ZZ, Chen JP, Zhao SL, et al. Apoptosisinducing effect of alternol on mouse lymphocyte leukemia cells and its mechanism［J］. Yao Xue Xue Bao, 2007, 42(12): 1259-1265. ［6］ Liu X, Wang J, Sun B, et al. Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803［J］. Invest New Drugs, 2007, 25(6): 505-517. DOI: 10.1007/s1063700790574. ［7］ Cong PF, Qu YC, Chen JP, et al. Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells［J］. World J Gastroentero, 2015, 21(15): 4526-4535. DOI: 10.3748/wjg.v21.i15.4526. ［8］ Zhu XL, Wang YL, Chen JP, et al. Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelialtomesenchymal transition［J］. Tumour Biol, 2014, 35(2): 1627-1635. DOI: 10.1007/s132770131224y. ［9］ Yeung ED, Morrison A, Plumeri D, et al. Alternol exerts prostateselective antitumor effects through modulations of the AMPK signaling pathway［J］. Prostate, 2012, 72(2): 165-172. DOI: 10.1002/pros.21417. ［10］ Tang Y, Chen R, Huang Y, et al. Natural compound Alternol induces oxidative stressdependent apoptotic cell death preferentially in prostate cancer cells［J］. Mol Cancer Ther, 2014, 13(6): 1526-1536. DOI: 10.1158/15357163.MCT130981. ［11］ Zuo D, Zhou Z, Wang H, et al. Alternol, a natural compound, exerts an antitumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways［J］. J Cell Mol Med, 2017, 21(2): 208-221. DOI: 10.1111/jcmm.12957. ［12］ Yao Y, Zhang B, Chen H, et al. Alteronol inhibits proliferation in HeLa cells through inducing a G1phase arrest［J］. J Pharm Pharmacol, 2012, 64(1): 101-107. DOI: 10.1111/j.20427158.2011.01375.x. ［13］ Su X, Gong P, Wang D, et al. Effect of alternol on the anticancer of mouse cervical carcinoma U14 cells［J］. Modern Oncol, 2012, 20(7): 1321-1324. ［14］ Wang Y, Zhu X, Duan LL, et al. Effects of alternol on the cell proliferation and apoptosis in human hepatocellular carcinoma cells［J］. J China Med Univ, 2013, 42(11): 999-1002. ［15］ Liu LL, Chen N, Yuan X, et al. The mechanism of alteronol inhibiting the proliferation of human promyelocytic leukemia HL60 cells［J］. Yao Xue Xue Bao, 2012, 47(11): 1477-1482. ［16］ Yang F, Ran F, Guo D, et al. Alteronol induced apoptosis of human lung cancer A549 cells［J］. J Shihezhi Univ, 2013, 31(3): 12-15. ［17］ Wang C, Zhang B, Chen N, et al. Alteronol induces differentiation of melanoma b16f0 cells［J］. Recent Pat Anticancer Drug Discov, 2015, 10(1): 116-127. ［18］ Ukeda H, Kawana D, Maeda S, et al. Spectrophotometric assay for superoxide dismutase based on the reduction of highly watersoluble tetrazolium salts by xanthinexanthine oxidase［J］. Biosci Biotechnol Biochem, 1999, 63(3): 485-488. DOI: 10.1271/bbb.63.485. ［19］ Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancerdrug screening［J］. J Natl Cancer Inst, 1990, 82(13): 1107-1112. ［20］ Strober W. Trypan blue exclusion test of cell viability［J］. Curr Protoc Immunol, 2001, Appendix 3: Appendix 3B. DOI: 10.1002/0471142735.ima03bs21. ［21］ Schmidt M, Deschner EE, Thaler HT, et al. Gastrointestinal cancer studies in the human to nude mouse heterotransplant system［J］. Gastroenterology, 1977, 72(5 Pt 1): 829-837. ［22］ Wang Z, Wang D, Liu L, et al. Alteronol inhibits the invasion and metastasis of B16F10 and B16F1 melanoma cells in vitro and in vivo［J］. Life Sci, 2014, 98(1): 31-38. DOI: 10.1016/j.lfs.2013.12.213. ［23］ Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROSmediated mechanisms: a radical therapeutic approach?［J］. Nat Rev Drug Discov, 2009, 8(7): 579-591. DOI: 10.1038/nrd2803. ［24］ Chen J, Chen N, Chen X, et al. Comparison of the antimetastasis effect of alternol and paclitaxel［J］. Chinese Pharma Bulletin, 2011, 27(8): 1111-1115. ［25］ Li W, Yin X, Duan LL, et al. Effect of alternol on DNA topoisomerase activity［J］. J China Med Univ, 2012, 41(10): 889-891.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.